“Global Protein Expression market set to grow to $3.2bn by 2024” says Visiongain report

24 October 2019
Pharma

Visiongain has launched a new pharma report Global Protein Expression Market Report: Cell-free Expression System, Prokaryotic/Bacterial Expression System, Yeast Cell Expression Systems, Algal-based Expression Systems, Insect Cell Expression Systems, Mammalian Cell Expression Systems, Reagents, Expression Vectors, Competent Cells, Instruments, Services, Therapeutic Applications, Industrial Application, Research Application, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs).

The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.

The lead analyst of the report commented "Recombinant proteins will continue to be essential reagents for drug discovery projects in the future and that technological developments will emerge to match changes in demand or to keep in step with advances in other application areas. Another great opportunity for future growth in the protein expression market is provided by emerging countries, especially China and India. Their markets are growing at a faster rate than that of the developed Western markets.

The demand for expertise in recombinant protein expression development is another opportunity for the market, and this will allow smaller niche companies to compete with the large multinational CROs, resulting in more companies entering the market and more products and services being offered."

Leading companies featured in the report include Agilent Technologies, Bio-Rad Technologies, EMD Milipore, New England Biolabs, Inc., Oxford Expression Technologies, Ltd., Promega Corporation, Qiagen NV, Takara Bio, Inc., Thermo Fisher Scientific, Inc. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever